跳转至内容
Merck

Y0000503

阿曲库铵杂质F

European Pharmacopoeia (EP) Reference Standard

别名:

苯磺酸阿曲库铵

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C65H82N2O18S2
CAS号:
分子量:
1243.48
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

atracurium

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

[O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c2ccccc2.COc3ccc(CC4c5cc(OC)c(OC)cc5CC[N+]4(C)CCC(=O)OCCCCCOC(=O)CC[N+]6(C)CCc7cc(OC)c(OC)cc7C6Cc8ccc(OC)c(OC)c8)cc3OC

InChI

1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2

InChI 密鑰

XXZSQOVSEBAPGS-UHFFFAOYSA-L

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Atracurium for impurity F identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Nicotinic acetylcholine receptor antagonist.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Michele Carron et al.
Anesthesiology, 117(2), 309-320 (2012-05-23)
The stress responses from tracheal intubation are potentially dangerous in patients with higher cardiovascular risk, such as obese patients. The primary outcome objective of this study was to test whether, in comparison with the endotracheal tube (ETT), the Proseal™ Laryngeal
A Movafegh et al.
European review for medical and pharmacological sciences, 17(4), 447-450 (2013-03-08)
Non-depolarizing neuromuscular blocking agents (NMB) differ in pharmacokinetic and pharmacodynamic parameters. An anesthesiologist according to these similarities and differences is able to choose the least costly one if the same safety profile and same clinical benefit achieved with the different
Maxime Gauberti et al.
Cerebrovascular diseases (Basel, Switzerland), 33(4), 329-339 (2012-02-22)
The lack of a relevant stroke model in large nonhuman primates hinders the development of innovative diagnostic/therapeutic approaches concerned with this cerebrovascular disease. Our objective was to develop a novel and clinically relevant model of embolic stroke in the anesthetized
Gudrun Schöffmann et al.
Veterinary anaesthesia and analgesia, 39(3), 256-265 (2012-03-17)
To determine the effects of age, sevoflurane and isoflurane on atracurium-induced neuromuscular blockade in 3-16 week-old lambs. Prospective randomized experimental trial. Twenty-six Scottish blackface ewe-lambs were anaesthetized for spinal surgery when either 3-6 (mean age 4.6 weeks; n = 18)
Mohammad R Ghodraty et al.
Journal of anesthesia, 26(6), 858-863 (2012-07-04)
During the induction of anesthesia, patients are at risk of aspiration while awaiting full muscle relaxation. Magnesium has been shown to have synergistic effects with neuromuscular blocking drugs. We tested if magnesium, as an adjunct, increases the speed of onset

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门